- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Rhett Wilkerson: Biosimilars and Patient Costs for Cancer Care
Rhett Wilkerson, associate director of patient financial services, Florida Cancer Specialists, discusses the role biosimilars have to play in reducing patient costs.
Transcript
Yeah, absolutely. And we've already seen that as well. A lot of the insurance companies are starting to dictate which biosimilars we switch to and when. I think it's a great benefit to the patient as well if we can find them something that is going to do the job as well and is appropriate and payable. You know, we're interested in in pursuing that option as well for the patients.
Newsletter
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
